Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics (IMUC ) has received access to BioWa’s patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
Subscribe to our email newsletter
Under the agreement, Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT Technology.
POTELLIGENT Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell.
Research shows that POTELLIGENTTechnology enhances ADCC activity of an antibody in vitro, and increases potency and efficacy of the antibody in vivo.
BioWa president and CEO Yasunori Yamaguchi said their decision to partner with IMUC was driven by their interest in novel therapeutic antibody targets in oncology that possess preclinical documentation.